	US 11,786,542 B2
	Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways
Atique U. Ahmed, Evanston, IL (US); Jack M. Shireman, Chicago, IL (US); and Cheol H. Park, Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by NORTHWESTERN UNIVERSITY, Evanston, IL (US)
Filed on Nov. 13, 2020, as Appl. No. 17/98,177.
Claims priority of provisional application 62/936,139, filed on Nov. 15, 2019.
Prior Publication US 2021/0145855 A1, May 20, 2021
Int. Cl. A61K 31/7056 (2006.01); A61K 31/343 (2006.01); A61K 31/495 (2006.01)

CPC A61K 31/7056 (2013.01) [A61K 31/343 (2013.01); A61K 31/495 (2013.01)]

8 Claims

1. A method of treating a proliferative cell disease or disorder in a subject in need thereof, the method comprising:

(a) administering to the subject a therapeutic agent that inhibits or reduces the biological activity of inosine-5′-monophosphate dehydrogenase 1 (IMDPH1) or inosine-5′-monophosphate dehydrogenase 2 (IMDPH2); and

(b) administering to the subject an alkylating agent,

wherein the therapeutic agent that inhibits or reduces the biological activity of IMDPH1 or IMDPH2 is selected from the group consisting of mizoribine, tiazofurin, mycophenolic mofetil, and mycophenolic acid.